An independent study of the preclinical efficacy of C2-8 in the R6/2 transgenic mouse model of Huntington's disease.

@article{Wang2013AnIS,
  title={An independent study of the preclinical efficacy of C2-8 in the R6/2 transgenic mouse model of Huntington's disease.},
  author={Nan Wang and Xiao-Hong Lu and Susana V Sandoval and X William Yang},
  journal={Journal of Huntington's disease},
  year={2013},
  volume={2 4},
  pages={443-51}
}
BACKGROUND C2-8 is a small molecule inhibitor of polyglutamine aggregation and can reduce photoreceptor neurodegeneration in a Drosophila model of Huntington's disease (HD). Further preclinical studies have shown that oral administration of C2-8 in R6/2 HD transgenic mice can penetrate into the brain, reduce mHTT-exon1 aggregation, improve motor performance… CONTINUE READING